Lonza, Thermo Fisher Scientific Inc., and BD dominated the North America Automated Cell Cultures Market in 2020

North America Automated Cell Cultures Market is expected to grow with a CAGR of 9.0% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/north-america-automated-cell-cultures-market

The North America automated cell cultures market is a highly fragmented market, which includes many key players. The market has witnessed increased strategic developments owing to favourable market scenarios.   

The major players dealing in the North America automated cell cultures market are introducing a strong range of products providers, launching new products, and adopting strategic initiatives such as acquisition, agreement, business expansion, award, and recognition. This helped companies to maximize sales with an enhanced product portfolio.

For instance:

  • In May 2021, Lonza launched the next generation of its popular Nucleofector Platform. It is an intuitive software that delivers flexibility and the trusted performance. This has helped the company to expand its product business portfolio

Lonza is the dominating player in the North America automated cell cultures market. The other key players existing in the market are Sartorius AG, Danaher, Nexcelom Bioscience LLC., HiMedia Laboratories, Cell Culture Company, LLC, Advanced Instruments, NanoEntek America, Inc., FUJIFILM Holdings America Corporation, Hitachi, Ltd., Kawasaki Heavy Industries, Ltd., Thrive Bioscience, Inc., Eppendorf AG, CellGenix GmbH, Scientica Instrumentation, Inc., ChemoMetec, PromoCell GmbH, Thermo Fisher Scientific Inc., BioSpherix, Ltd., Merck KGaA, Tecan Trading AG, Hamilton Company, BD, Benchmark Scientific, Inc., RWD Life Science Co., LTD, Cytiva (A subsidiary of Danaher Corporation), Corning Incorporated, Bulldog-Bio and among others.

North America Automated Cell Cultures Market LONZA.

Lonza has headquarters in Basel, Switzerland, and was founded in 1897. It has public ownership. The company focuses on enabling treatments that prevent illness and supports healthier lifestyles, optimizes scientific innovation and manufacturing technology to enable its customers to serve their patients and consumers.

The company operates its business through two business segments, Lonza Pharma Biotech

& Nutrition, Lonza Speciality Ingredients. Under which Lonza Speciality Ingredients is the market-focused segment. The company has wide product categories such as primary and stem cells, Cell Bio Services, Bioprocessing Media, Culture Media & Reagents, 3D Culture Products, ADME & Toxicology, Transfection, Cell Analysis, Electrophoresis, and Endotoxin Detection. Under which Culture Media & Reagents is the market-focused category. The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In August 2021, Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, announced that it would invest in establishing drug product manufacturing capabilities at its site in Guangzhou, China. The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services

The company has a wide presence across Europe, North and Central America, Latin America, Asia, Africa.

The company also has various subsidiary companies such as Lonza KK (Japan), Lonza NZ Limited (New Zealand), Lonza India Private Limited (India), Lonza Bioscience Singapore Pte Ltd (Singapore), Lonza Consumer Health Inc. (United States), among others.

THERMOFISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. was found in 1960. The companies headquarter is in Massachusetts, U.S. It has public ownership. The company is focused on manufacturing scientific instruments, consumables, and chemicals. The company operates in four business segments such as Life Science Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products & Services. Under which Laboratory Products & Services is the market-focused segment. The company has various product categories such as Lifesciences, Industrial & Applied Sciences, Clinical & Diagnostics, Lab Solutions, Digital Solutions, Brands. Under which Lifesciences is the market-focused category. The company is attaining lucrative growth through several strategic initiatives.  

  • In April 2021, Thermo Fisher Scientific Inc entered into a definitive agreement with PPD, Inc. According to the agreement, the company will acquire PPD, Inc. for USD 47.50/share of a total worth of USD 17.4 Billion. The agreement will help the company to develop new competencies and resources.

The company has a wide presence in the Americas, Europe, Asia-Pacific, Middle East, and Africa. The company also has various subsidiary companies such as Patheon (U.S.), Dionex (U.S.), Cole Palmer (U.S.), Affymertrix (U.S.), Applied Biosystems (U.S.), Thermo Trace Limited (Australia), Laboratory Management Systems Inc. (Delaware), Jouan Nordics AS (Denmark), among others.

BD

BD has headquarters in New Jersey, U.S., founded in 1897. It has public ownership. The company is engaged in developing, manufacturing, and selling a broad range of medical supplies, devices, laboratory equipment, and diagnostic products used by healthcare institutions also provides customer solutions that are focused on improving medication management and patient safety. The company has various business segments such as BD Medical, BD Life Science, BD Interventional. Under which BD Life Science is the market-focused segment.

 The company has various product categories that are Anesthesia Delivery, Biopsy, Biosciences, Bio surgery, Cervical Cancer Screening, Diabetes Care, Drainage, Drug Delivery System, Gastrointestinal Care, Hazardous Drug Safety, Hernia Repair, and Fixation, Homecare, Infection Prevention, Infusion Therapy, Interventional Specialties, Lab Automation, Medication and Supply Management, Microbiology Solution, Molecular Diagnostic, Patient Monitoring, Prostrate Health, Respiratory Care, Sharp Disposal Solution, Software Solution, Specimen Collection, Surgical Instruments, Syringes and Needles, Urology and Kidney Health, Vascular Access, Vascular Surgery, and Wound Care. Under which Microbiology Solution is the market-focused category.

The company is attaining lucrative growth through several strategic initiatives.

For instance,

  • In June 2021, BD participated in the International Society for the Advancement of Cytometry. This has helped the company to discuss the advancements in the field of immunology and immune-oncology

The company has a presence in Americas, Europe, Asia-Pacific, Middle East, and Africa. The company also has various subsidiary companies such as Care Fusion (U.S.), C. R. Bard (U.S.), Accuri Cytometers Inc. (U.S.), Becton Dickson UK ltd. (U.K.), Straub medical AG (Switzerland), among others.